These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27138868)

  • 41. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies.
    Civoli F; Finck B; Tang H; Hodge J; O'Kelly H; Vexler V
    Adv Ther; 2022 Mar; 39(3):1230-1246. PubMed ID: 35034311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men.
    Matsuguma K; Matsuki S; Sakamoto K; Shiramoto M; Nakagawa M; Kimura M; Irie S; Kaneko D; Ohnishi A
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):99-104. PubMed ID: 27128214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.
    Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R
    BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
    Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
    BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
    Schwabe C; Illes A; Ullmann M; Ghori V; Vincent E; Petit-Frere C; Monnet J; Racault AS; Wynne C
    Expert Rev Clin Immunol; 2022 May; 18(5):533-543. PubMed ID: 35354411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving white blood cell equity: are the safety profiles of biosimilar and reference pegfilgrastims comparable?
    Loaiza-Bonilla A; Page RD
    Future Oncol; 2024 Jan; 20(3):145-158. PubMed ID: 37609795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Revisiting same day administration of pegfilgrastim in the age of biosimilars: A review of literature.
    Gerberich AJ; Attilio MR; Svoboda A
    J Oncol Pharm Pract; 2020 Dec; 26(8):1970-1976. PubMed ID: 32903142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
    Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
    Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.
    Roskos LK; Lum P; Lockbaum P; Schwab G; Yang BB
    J Clin Pharmacol; 2006 Jul; 46(7):747-57. PubMed ID: 16809800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study.
    Takács I; Jókai E; Kováts DE; Aradi I
    Osteoporos Int; 2019 Mar; 30(3):675-683. PubMed ID: 30357438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacodynamic and Pharmacokinetic Equivalences of Epoetin Hospira and Epogen(®) After Multiple Subcutaneous Doses to Healthy Male Subjects.
    Stalker D; Ramaiya A; Kumbhat S; Zhang J; Reid S; Martin N
    Clin Ther; 2016 May; 38(5):1090-101. PubMed ID: 27112531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
    Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
    Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bioequivalence of a biosimilar enoxaparin sodium to Clexane
    Martínez González J; Monreal M; Ayani Almagia I; Llaudó Garín J; Ochoa Díaz de Monasterioguren L; Gutierro Adúriz I
    Drug Des Devel Ther; 2018; 12():575-582. PubMed ID: 29593380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of peripheral blood stem cell mobilization with filgrastim versus pegfilgrastim in lymphoma patients - single center experience.
    Lipan L; Colita A; Stefan L; Calugaroiu C; Serban C; Tomuleasa C; Pasca S; Colita A; Tanase A
    J BUON; 2021; 26(3):1080-1087. PubMed ID: 34268975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
    Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
    Eto T; Karasuyama Y; González V; Del Campo García A
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
    Hettema W; Wynne C; Lang B; Altendorfer M; Czeloth N; Lohmann R; Athalye S; Schliephake D
    Expert Opin Investig Drugs; 2017 Aug; 26(8):889-896. PubMed ID: 28651442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
    Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.